Search Results
Your search for ,kEY matches 7151 pages
Showing 1 - 50Association of Body Size and Bladder Cancer Risk
In a study—The Pooling Project of Prospective Studies of Diet and Cancer—reported in the Journal of Clinical Oncology, Milne et al in the National Cancer Institute Cohort Consortium found that increased body size is associated with increased risk of bladder cancer among men, but not among women....
Melanoma: Gut Microbiome May Help Predict Recurrence After Immunotherapy
Gut bacterial markers may be able to predict recurrence in patients with high-risk melanoma receiving adjuvant immune checkpoint inhibition, according to study findings published in Cell. “Our study identified for the first time gut bacterial types that can serve as markers of increased recurrence ...
Lenalidomide Plus Rituximab in Relapsed or Refractory Indolent Non-Hodgkin Lymphoma: 5-Year Follow-up From AUGMENT
As reported in the Journal of Clinical Oncology by Leonard et al, the 5-year follow-up of the phase III AUGMENT trial has shown continued benefit of lenalidomide plus rituximab (R2) vs rituximab with placebo (R-placebo) in patients with relapsed or refractory indolent non-Hodgkin lymphoma. Study...
Atezolizumab in Alveolar Soft Part Sarcoma: Long-Term Follow-up
As reported in the Journal of Clinical Oncology by Chen et al, extended follow-up of the pivotal phase II trial of atezolizumab in patients with alveolar soft part sarcoma (ASPS) showed continued benefit of atezolizumab treatment. Study Details In the U.S. multicenter trial, 53 patients received...
Belzutifan/Lenvatinib Outperforms Cabozantinib After Checkpoint Inhibitors in Advanced Renal Cell Carcinoma
At the first and second interim analyses of the phase III LITESPARK-011 trial, treatment with the novel first-in-class hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor belzutifan plus lenvatinib improved progression-free survival, produced a higher objective response rate, and showed a trend...
Can Pesticide Exposure Increase Early-Onset Colorectal Cancer Risk?
A new study has identified for the first time the exposome footprint—the set of environmental and lifestyle exposures—for colorectal cancer occurring in patients younger than age 50 through epigenetic signatures. By comparatively analyzing DNA methylation patterns in patients under and over 50, the ...
Metabolic Tumor Volume Predicts CAR T-Cell Therapy Response in LBCL
Positron-emission tomography (PET)-based metabolic tumor volume could serve as a significant measure of response to chimeric antigen receptor (CAR) T-cell therapy in patients with large B-cell lymphoma, according to the results of a study published in The Journal of Nuclear Medicine. Metabolic...
MIBC: Pembrolizumab With Trimodal Therapy for Bladder Preservation
Pembrolizumab in combination with gemcitabine and concurrent hypofractionated radiation therapy and maximal transurethral resection may be safe and feasible in patients with muscle-invasive bladder cancer (MIBC), allowing many patients to potentially avoid cystectomy, according to the results of a...
Long-Term Outcomes With Taletrectinib in ROS1-Positive NSCLC
As reported in the Journal of Clinical Oncology by Li et al, long-term follow-up of a Chinese phase II trial (TRUST-I) showed prolonged activity with taletrectinib in patients with ROS1 mutation–positive non–small cell lung cancer (NSCLC). Study Details In the multicenter trial, 173 patients had...
Amivantamab in Chemorefractory RAS/BRAF Wild-Type Metastatic Colorectal Cancer
In a phase Ib/II study (OrigAMI-1) reported in the Journal of Clinical Oncology, Oberstein et al found that the EGFR-MET bispecific antibody amivantamab-vmjw showed activity when used as monotherapy in patients with chemorefractory RAS/BRAF wild-type metastatic colorectal cancer. Study Details In...
Tracking Biological Age Changes Gives Insights Into Cancer Prognosis
Face aging rate, a measure of changes in biological age over time, could serve as a noninvasive prognostic biomarker for determining outcomes in patients with cancer, according to the results of a study published in Nature Communications. “Deriving a Face Aging Rate from multiple, routine facial...
Neoadjuvant Durvalumab and Chemotherapy in Triple-Negative Breast Cancer: Long-Term Follow-Up of GeparNuevo Trial
As reported in the Journal of Clinical Oncology by Loibl et al, long-term analysis of the German phase II GeparNuevo trial showed continued benefit in outcomes with neoadjuvant durvalumab vs placebo followed by dose-dense epirubicin/cyclophosphamide in patients with triple-negative breast cancer....
RAS Inhibitor Daraxonrasib in Metastatic Pancreatic Cancer
The treatment landscape for advanced pancreatic cancer is shifting. The common RAS mutation is now targetable and the race for the most effective inhibitor is heating up. In mid-April, Revolution Medicines announced positive results from its phase III RASolute 302 clinical trial of daraxonrasib, an ...
Early-Onset Lung Cancer May Be Connected to Pesticide Contaminants
Dietary patterns in young patients with lung cancer suggest that many have higher dietary quality scores than average U.S. reference values, according to results from a study presented at the American Association for Cancer Research (AACR) Annual Meeting 2026 (Abstract 5039). The researchers...
Breast Cancer: Clonal Hematopoiesis and Risk of Trastuzumab-Related Cardiotoxicity
In a cohort study reported in JAMA Oncology, Park et al found that clonal hematopoiesis of indeterminate potential (CHIP) was associated with an increased risk of trastuzumab-related cardiotoxicity in patients with breast cancer. Study Details The analysis involved data from the UK Biobank...
Novel Therapies Improve Outcomes Across Hematologic Malignancies
In an effort to help clinicians stay current with rapidly evolving hematology-oncology literature, we are providing these concise, clinically focused summaries of important peer-reviewed studies. These summaries are intended to highlight key findings, study design, and outcomes that may inform...
Update to Patient–Clinician Communication Guideline Provides Recommendations on Telehealth, Boundary-Setting
ASCO has updated its guideline on patient–clinician communication, providing recommendations on a range of best practices for explaining treatment options and goals of care, conversing with patients’ support networks, communicating among care team members, and setting boundaries.1 The update to the ...
AMA Data Show Nearly 50% of Surveyed Oncologists Reported Burnout in 2025
New data from the American Medical Association (AMA) show physician burnout continuing to decline nationwide, but significant differences across medical specialties underscore the need for more targeted solutions within health systems. In 2025, 41.9% of physicians reported experiencing at least one ...
Long-Term Immunotherapy for Alveolar Soft Part Sarcoma
Long-term adverse events were rare and manageable among patients with alveolar soft part sarcoma (ASPS), which primarily affects adolescents and young adults, who received immunotherapy beyond the standard 2 years, according to results from a phase II clinical trial presented at the American...
Overall Survival With Addition of Relacorilant to Nab-Paclitaxel in Platinum-Resistant Ovarian Cancer
As reported in The Lancet by Lorusso et al, the phase III ROSELLA trial has shown an improvement in overall survival with the addition of relacorilant to nab-paclitaxel in patients with platinum-resistant ovarian cancer. Relacorilant is a selective glucocorticoid receptor antagonist that acts to...
Tislelizumab With Induction Chemotherapy and Concurrent Chemoradiotherapy in Locally Advanced Esophageal Cancer
In a Chinese phase II trial (EC-CRT-002) reported in the Journal of Clinical Oncology, Chen et al found that the addition of the anti–PD-1 monoclonal antibody tislelizumab without maintenance cycles to induction chemotherapy and concurrent chemoradiotherapy significantly improved progression-free...
Perioperative Pembrolizumab in Localized Colorectal Cancer With dMMR/MSI
In a French phase II study (IMHOTEP) reported in the Journal of Clinical Oncology, de la Fouchardière et al found that perioperative pembrolizumab was active in previously untreated resectable localized colorectal cancer with mismatch repair deficiency (dMMR)/microsatellite instability (MSI). Study ...
Unique Phase I NSCLC Trial Sites Decreasing in United States
The number of unique clinical trial sites in the United States with phase I studies for patients with non–small cell lung cancer (NSCLC) decreased by 44% from 2020 to 2024, showing a significant consolidation of studies to only high trial volume sites in the country, according to the results of a...
Early-Onset ICI-Related Myocarditis Linked to Increased Mortality
Early-onset of immune checkpoint inhibitor (ICI)–related myocarditis was associated with an increased risk for myocarditis fatality, according to the results of a study presented at the American Association for Cancer Research (AACR) Annual Meeting 2026 (Abstract 5212). The researchers suggested...
First-Line Zongertinib in Advanced HER2-Mutant NSCLC
In a phase IA to IB trial reported in The New England Journal of Medicine, Heymach et al found that first-line zongertinib was active in patients with advanced or metastatic HER2-mutant non–small cell lung cancer (NSCLC). As noted by the investigators, zongertinib is an oral, irreversible tyrosine...
Pretreatment MRI Prognostic Information After Radical Prostatectomy
In a systematic review and meta-analysis reported in JAMA Oncology, Agrotis et al found that pretreatment MRI provided important prognostic information after radical prostatectomy in patients with prostate cancer. Study Details A literature review was conducted through March 2025. Studies were...
Exposure to Wildfire Smoke May Be Linked to Increased Risk of Developing Several Types of Cancer
Exposure to wildfire smoke was associated with a significantly increased risk of lung, colorectal, breast, bladder, and blood cancers, according to results from a study presented at the American Association for Cancer Research (AACR) Annual Meeting 2026 (Abstract 6252). Although it’s known that...
Methylation-Based AI Model Classifies Tumors of Unknown Origin
An artificial intelligence (AI) model using DNA methylation patterns was able to classify tumors of unknown origin with high accuracy, according to the results of a study presented at the American Association for Cancer Research (AACR) Annual Meeting 2026 (Abstract 3869). “One of the most...
Initial Data Shows Safety for WEE1/PKMYT1 Inhibitor Combination in Advanced Solid Tumors
Initial data from the phase I study of WEE1 inhibitor zedoresertib and PKMYT1 inhibitor lunresertib demonstrated an expected and manageable safety profile in patients with advanced solid tumors harboring CCNE1, FBXW7, or PPP2R1A gene alterations, according to findings from the MYTHIC trial...
Elisrasib Demonstrates High Disease Control Rate in KRAS G12C–Mutant NSCLC
Elisrasib, a next-generation KRAS G12C inhibitor, demonstrated disease control in a majority of patients with KRAS G12C–mutated non–small cell lung cancer (NSCLC), whether exposed to a prior KRAS G12C inhibitor or not, according to findings from an ongoing phase I/II clinical trial presented at the ...
Zoldonrasib in Patients With KRAS G12D–Mutant NSCLC Previously Treated With Chemoimmunotherapy
The investigational KRAS G12D inhibitor zoldonrasib had a favorable safety profile and induced antitumor activity in some patients with KRAS G12D–mutated non–small cell lung cancer (NSCLC) who were previously treated with chemotherapy and immunotherapy, according to preliminary findings from an...
Treatment Modifications and Outcomes for Older Adults With Advanced Cancer Who Prefer Preserving QOL vs Prolonging Survival
As reported in JAMA Oncology by Richardson et al, a secondary analysis of the GAP70+ trial showed that treatment modifications and outcomes did not differ between older patients with advanced cancer who prioritized quality of life (QOL) vs those who preferred prolonging survival. Study Details This ...
Melanoma: Can AI Enable Diagnosis Prediction?
Assessment of machine-learning models tested on Swedish registry data enabled more accurate melanoma diagnosis prediction, with added health-care code, age, sex, and medication information for improved performance, according to the results of a study published in Acta Dermato-Venereologica. “Our...
AI Tool Shows Early Ability in Pinpointing Cells Driving Aggressive Cancers
Researchers have developed an artificial intelligence (AI) tool that can identify small groups of cells most responsible for driving aggressive cancers. The tool, called SIDISH, offers scientists a clearer path to designing targeted therapies by showing which cells inside a tumor are most strongly...
Sequential or Concurrent Radiotherapy and Immunotherapy in Advanced Newly Diagnosed or Refractory NSCLC
In a Chinese cohort study (OCEANUS) reported in JAMA Oncology, Zhou et al found that sequential radiotherapy (RT) and immune checkpoint inhibitor (ICI) therapy was associated with better overall survival vs concurrent RT and ICI therapy in patients with advanced newly diagnosed or refractory...
Romiplostim for Chemotherapy-Induced Thrombocytopenia
In a phase III trial (RECITE) reported in The New England Journal of Medicine, Al-Samkari et al found that the thrombopoietin receptor agonist romiplostim was effective in treating chemotherapy-induced thrombocytopenia (CIT) among patients receiving oxaliplatin-based multiagent cytotoxic...
AYA Cancer Survivors and Risk for Earlier Subsequent Primary Neoplasms
About one in six survivors of an adolescent and young adult cancer will develop a subsequent primary neoplasm within 30 years of their original diagnosis, according to the results of a population-based study published in the Canadian Medical Association Journal. “When combined with the relatively...
ASH/ISTH Create Guidelines for Pediatric VTE Prophylaxis
The American Society of Hematology (ASH) and the International Society on Thrombosis and Haemostasis (ISTH) have released a set of comprehensive clinical practice guidelines for the use of anticoagulant prophylaxis in pediatric patients at risk of venous thromboembolism. The guidelines were...
Asbestos-Free Talc Not Associated With Increased Risk for Respiratory Cancers
Occupational exposure to asbestos-free talc did not increase the risk for lung, mesothelioma, or laryngeal cancers, according to the results of a systemic review and meta-analysis published in the Journal of Thoracic Oncology. The study authors, including corresponding author and lead researcher...
LuPSMA-617 and Pembrolizumab in mCRPC
In an Australian phase IB to II study (PRINCE) reported in The Lancet Oncology, Sandhu et al found that the combination of lutetium-177–labeled PSMA-617 (LuPSMA-617) and pembrolizumab showed “encouraging” activity in patients with metastatic castration-resistant prostate cancer (mCRPC). As stated ...
New Molecular-Based Model for Classification and Risk in Chronic Myelomonocytic Leukemia
As reported in the Journal of Clinical Oncology, Lanino et al have developed a new model (international chronic myelomonocytic leukemia [CMML] prognostic scoring system [iCPSS]) for characterizing CMML by combining molecular information with clinical information. Study Details The study involved...
Large Language Models May Generate Concise, Coherent Pathology Summaries, Reducing Physician Burden
Large language models performed better than physicians at producing accurate and comprehensive oncology pathology report summaries, according to the results of a study published in JCO Clinical Cancer Informatics. Six large language models were tested in the study, and most generated summaries...
Nancy L. Lewis, MD, MBS, FACP, Named NCCN’s New Chief Scientific Officer
The National Comprehensive Cancer Network® (NCCN®) has announced the selection of Nancy L. Lewis, MD, MBS, FACP, as its new Chief Scientific Officer (CSO). Dr. Lewis is an experienced biomedical researcher with expertise in clinical trials for treating solid tumors and hematologic malignancies....
Global Survival Index for Childhood Cancer: CONCORD-4
As reported in The Lancet, Allemani et al identified findings in the CONCORD-4 study indicating the degree of progress towards the World Health Organization (WHO) Global Initiative for Childhood Cancer (GICC) target of 60% 5-year survival for all childhood cancers combined by the year 2030. Study...
Can Saying ‘I Do’ Reduce Cancer Risk?
A U.S. population-based study across demographic groups and cancer types found that ever-married adults consistently had a lower cancer risk compared with never-married individuals. Published in Cancer Research Communications, these findings suggest that marital status may serve as a valuable...
Analysis of Constitutional Cancer Predisposition Gene Variants in Nearly 15,000 Patients
In a UK retrospective cohort study reported in The Lancet Oncology, Whitworth et al analyzed the frequency of germline genetic variants in patients with cancer in the 100,000 Genomes Project. Study Details The study included data from 14,765 individuals with cancer entered into the 100,000 Genomes...
Electroacupuncture May Relieve Cognitive, Psychological Symptoms in Breast Cancer Survivors in Pilot Study
Electroacupuncture may alleviate some persistent neuropsychiatric symptoms experienced by breast cancer survivors, including psychological distress and cognitive impairment, according to the results of a randomized, double-blinded pilot trial published in the Journal of the National Cancer...
Colorectal Cancer: Duloxetine Not Effective in Preventing Oxaliplatin-Induced Peripheral Neuropathy
The antidepressant duloxetine was unable to prevent sensory oxaliplatin-induced peripheral neuropathy more significantly than placebo in patients with colorectal cancer receiving chemotherapy, according to the results of the Alliance A221805 trial published in JCO Oncology Advances. “Since we know ...
American Cancer Society Announces New Pediatric, Adolescent, and Young Adult Cancer Journal
The American Cancer Society (ACS) has announced the launch of its fourth medical journal, Pediatric, Adolescent & Young Adult Cancer. This international, multidisciplinary publication will feature peer-reviewed original research and solicited content on the latest advances in cancers affecting...
Advanced Prostate Cancer: Radiographic Progression and PSA Increase in Patients Treated With Enzalutamide
In a post hoc analysis of the phase III ARCHES and PROSPER trials reported in the Journal of Clinical Oncology, Armstrong et al found that radiographic progression (rPD) often occurred without prostate-specific antigen (PSA) rise in patients with advanced prostate cancer receiving the androgen...
